McKay J A, Douglas J J, Ross V G, Curran S, Ahmed F Y, Loane J F, Murray G I, McLeod H L
Department of Medicine and Therapeutics, University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, Scotland, United Kingdom.
Clin Cancer Res. 2000 Mar;6(3):1113-8.
Analysis of tumor markers focuses on expression in primary tumors with the assumption that this is representative of metastatic tumor, against which treatment is targeted. Few studies have compared the expression of such markers in primary and secondary tumors. In this study, several key genes involved in cell cycle regulation were investigated in colorectal tumors and corresponding lymph node metastases. The cell cycle regulators p53, cyclin D1, p21, p27, retinoblastoma protein (Rb), and proliferating cell nuclear antigen (PCNA) were examined in a series of 42 paired samples of primary colorectal and secondary lymph node tumors by immunohistochemistry. Expression of p53, p27, and Rb was similar in virtually all paired samples (p53, 38 of 42; p27, 39 of 42; Rb, 40 of 42), indicating that the pattern of these proteins in colorectal tumors may be used to predict that in lymph node tumors. It also suggests a lack of direct involvement in the metastatic process. A lower concordance for p21 and cyclin D1 staining was observed between primary and secondary tumors (p21, 19 of 42; cyclin D1, 22 of 42). p21 expression was more often observed in primary colorectal cancers, whereas cyclin D1 expression was more frequently seen in lymph node metastases, in keeping with the contrasting roles of these proteins as a cell cycle inhibitor (p21) and activator (cyclin D1). The PCNA-labeling index was found to vary considerably in a number of cases, thus limiting the ability to predict expression of this protein in lymph node metastases from the primary tumor. In addition, PCNA-labeling indices between paired samples were neither consistently higher nor lower, suggesting that the proliferative capacity of tumor cells is not directly related to their ability to metastasize.
肿瘤标志物分析主要关注其在原发性肿瘤中的表达情况,并假定这代表了转移性肿瘤,而治疗正是针对转移性肿瘤进行的。很少有研究比较这些标志物在原发性和继发性肿瘤中的表达。在本研究中,对结直肠癌及其相应淋巴结转移灶中几个参与细胞周期调控的关键基因进行了研究。通过免疫组织化学方法,在42对原发性结直肠癌和继发性淋巴结肿瘤样本中检测了细胞周期调节因子p53、细胞周期蛋白D1、p21、p27、视网膜母细胞瘤蛋白(Rb)和增殖细胞核抗原(PCNA)。在几乎所有配对样本中,p53、p27和Rb的表达相似(p53,42对中有38对;p27,42对中有39对;Rb,42对中有40对),这表明这些蛋白在结直肠癌中的表达模式可用于预测淋巴结肿瘤中的表达模式。这也提示它们在转移过程中缺乏直接参与。原发性和继发性肿瘤之间p21和细胞周期蛋白D1染色的一致性较低(p21,42对中有19对;细胞周期蛋白D1,42对中有22对)。p21表达更常见于原发性结直肠癌,而细胞周期蛋白D1表达更常见于淋巴结转移灶,这与这些蛋白作为细胞周期抑制剂(p21)和激活剂(细胞周期蛋白D1)的相反作用相符。发现PCNA标记指数在许多病例中差异很大,因此限制了根据原发性肿瘤预测该蛋白在淋巴结转移灶中表达的能力。此外,配对样本之间的PCNA标记指数既不是始终较高也不是始终较低,这表明肿瘤细胞的增殖能力与其转移能力没有直接关系。